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What\'s new?For participants of European origin, HbA~1c~ values defined as impaired glucose regulation (prediabetes) were cross‐sectionally associated with coronary heart disease, cerebrovascular disease and the composite outcome of cardiovascular disease.By contrast, in South Asian participants prediabetes defined according to HbA~1c~ concentration was non‐significantly associated with cerebrovascular disease only, and associations between HbA~1c~ concentration‐defined prediabetes and overall cardiovascular disease were absent and, thus significantly weaker, than those seen in the European participants.This suggests that current prediabetes HbA~1c~ thresholds may be inappropriate in South Asian groups as prediabetes defined in this way did not appear to confer excess cardiovascular risk in this ethnic group.

Introduction {#dme12895-sec-0006}
============

In parallel to the global diabetes epidemic, population surveys indicate a burgeoning prevalence of impaired glucose regulation, often termed prediabetes hyperglycaemia (12--29%, depending on definition) [1](#dme12895-bib-0001){ref-type="ref"}. Although it is clear that the term 'prediabetes' is misleading, as not all those with prediabetes will develop diabetes, it is acknowledged that this may represent a high cardiovascular disease risk state, with implications for intervention [2](#dme12895-bib-0002){ref-type="ref"}. It is in that latter sense that we use this term. Conventionally, prediabetic states have been defined by either post‐glucose challenge \[impaired glucose tolerance (IGT)\] or fasting glycaemia \[impaired fasting glycaemia (IFG)\] [3](#dme12895-bib-0003){ref-type="ref"}, but recently, guidelines for HbA~1c~‐based definitions of prediabetes have been published [2](#dme12895-bib-0002){ref-type="ref"}, [4](#dme12895-bib-0004){ref-type="ref"}.

Relatively more prediabetes is identified by HbA~1c~ than by IFG/IGT criteria in people of South Asian origin, whereas prevalence is similar by either criterion in populations of European origin [5](#dme12895-bib-0005){ref-type="ref"}. It is unclear how the greater prevalence of HbA~1c~‐identified prediabetes in this former group translates to cardiovascular risk, with some authors suggesting the HbA~1c~ definition of prediabetes may be less discriminative [6](#dme12895-bib-0006){ref-type="ref"}. As far as we are aware, this has never before been studied in South Asian populations; the majority of studies that have compared associations between prediabetes and cardiovascular disease by diagnostic criteria are in populations of European origin [7](#dme12895-bib-0007){ref-type="ref"}, [8](#dme12895-bib-0008){ref-type="ref"}, [9](#dme12895-bib-0009){ref-type="ref"}, [10](#dme12895-bib-0010){ref-type="ref"}. Moreover, our previous work suggests that associations between diabetes and cardiovascular disease (CVD) vary with ethnicity, with stronger associations in South Asian than in European populations [9](#dme12895-bib-0009){ref-type="ref"}, [11](#dme12895-bib-0011){ref-type="ref"}. Whether similar ethnic differences exist for associations between prediabetes and CVD risk is unclear.

The aims of the present study were to establish whether associations between prediabetes and subclinical and clinical cardiovascular disease risk differ between UK European and South Asian ethnic groups and whether any ethnic differences in associations were related to the definition of prediabetes used.

Subjects and methods {#dme12895-sec-0007}
====================

We used cross‐sectional data from the Southall and Brent Revisited (SABRE) study, a multi‐ethnic population‐based cohort of individuals living in north‐west London [12](#dme12895-bib-0012){ref-type="ref"}. The South Asian participants were first‐generation migrants; 82% were born in the Indian subcontinent and 14% in East Africa. Participants aged 40--70 years (*n* = 4056) were randomly selected from age‐ and gender‐stratified general practitioner lists and workplaces at baseline (1988--1991), and followed up (2008--2011) when aged 58‐85 years (*n* = 2671). The present analysis concerns the 682 European and 520 South Asian participants who attended the follow‐up clinic. All participants gave written informed consent. Study approval was obtained from St Mary\'s Hospital Research Ethics Committee (07/H0712/109).

Smoking status, alcohol consumption and medication receipt were ascertained from a health and lifestyle questionnaire [12](#dme12895-bib-0012){ref-type="ref"}. Physical activity comprised the total weekly energy expenditure (MJ), as previously described [13](#dme12895-bib-0013){ref-type="ref"}. Blood pressure was obtained three times after a 15‐min rest with an Omron CEP 7050 (Omron, Tokyo, Japan); the mean of the final two readings was used in the analysis. Glucose levels, lipid profile, HbA~1c~ and C‐reactive protein levels were measured on fasting blood samples, and anthropometry performed [13](#dme12895-bib-0013){ref-type="ref"}, [14](#dme12895-bib-0014){ref-type="ref"}. In addition, an abdominal computed tomography (CT) slice was taken to measure visceral adipose tissue area [13](#dme12895-bib-0013){ref-type="ref"}. Participants without known diabetes underwent an oral glucose tolerance test (OGTT).

Cardiac CT scanning was performed in all participants from the ascending aorta above the level of the coronary arteries to the inferior border of the heart. Coronary artery calcification was quantified using proprietary software on a Phillips Extended Brilliance computer workstation (Phillips Healthcare, Eindhoven, The Netherlands), and calcification was defined as an area \>1 mm^2^ of density \>130 Hounsfield units. The coronary artery calcification score was calculated as the sum of all lesion scores \[Agatston units (AU)\]. Scans were read by a single experienced observer blinded to participant ethnicity. Interobserver reproducibility, comparing scores from a senior investigator (A.W.) and intra‐observer reproducibility were assessed initially and at intervals during follow‐up, using the same 20 CT scans. The intra‐class correlation coefficient for intra‐ and inter‐observer measurements was 0.94. Subclinical coronary heart disease (CHD) was classified as a coronary artery calcification score \>400 AU [15](#dme12895-bib-0015){ref-type="ref"}.

Cerebral magnetic resonance imaging (MRI) scans provided data on brain infarcts ≥3 mm, a subclinical measure of cerebrovascular disease. We used an MRI scanning and scoring protocol based on that of the Cardiovascular Health Study [16](#dme12895-bib-0016){ref-type="ref"}. Whole‐brain scans included sagittal T1‐weighted images and axial T1‐weighted, proton density and T2‐weighted images of 5‐mm thickness, with no gaps. Thin‐section 3‐mm axial fluid attenuated inversion recovery (FLAIR) and coronal 1.5‐mm three‐dimensional T1‐weighted gradient echo images were also obtained. Scans were performed using a General Electric 1.5T or 3T scanners. Only infarcts of ≥3 mm were assessed, as smaller lesions are less reproducible [14](#dme12895-bib-0014){ref-type="ref"}. Inter‐ and intra‐observer reproducibility were evaluated for the presence of brain infarcts ≥3 mm on 44 scans; inter‐observer κ was 0.68 and intra‐observer κ was 0.79.

We used three classification systems to define glycaemic status for participants without existing diabetes. Firstly, WHO 1999 criteria were used to define prediabetes \[either impaired fasting glycaemia (fasting glucose ≥6.1 mmol/l and \<7.0 mmol/l) or impaired glucose tolerance (2‐h OGTT plasma glucose ≥7.8 mmol/l and \<11.1 mmol/l)\] and new diabetes (fasting glucose ≥7.0 mmol/l or 2‐h OGTT plasma glucose ≥11.1 mmol/l\] [3](#dme12895-bib-0003){ref-type="ref"}. Secondly, glycaemic categories according to the International Expert Committee (IEC) 2009 criteria [2](#dme12895-bib-0002){ref-type="ref"} were based on the following HbA~1c~ thresholds: prediabetes, HbA~1c~ ≥42 mmol/mol (6.0%) but \< 48 mmol/mol (6.5%); new diabetes, HbA~1c~ ≥48 mmol/mol (6.5%). We also studied glycaemia according to the American Diabetes Association (ADA) 2014 recommendations [4](#dme12895-bib-0004){ref-type="ref"}, which advocate HbA~1c~ thresholds of ≥39 mmol/mol (5.7%) but \<48 mmol/mol (6.5%) for prediabetes and ≥48 mmol/mol (6.5%) for new diabetes. Analyses were conducted using the IEC HbA~1c~ prediabetes threshold unless otherwise stated. Pre‐existing diabetes was identified from primary care record review or participant questionnaire (recall of physician‐diagnosed diabetes plus diagnosis year or diabetes medication).

Coronary heart disease was defined firstly from primary care record review adjudicated by two clinicians, as per Anglo‐Scandinavian Cardiac Outcomes Trial (ASCOT) criteria [17](#dme12895-bib-0017){ref-type="ref"}. Additionally, International Classification of Disease (ICD)‐9 codes 410‐415 and ICD‐10 codes I200‐I259 from Hospital Episode Statistics and codes K401‐K469, K491‐K504, K751‐K759 and U541 from the Office of Populations and Surveys classification of interventions and procedures identified CHD. For stroke, primary care data were reviewed in a similar manner to that used for CHD, with diagnoses made again according to ASCOT criteria [17](#dme12895-bib-0017){ref-type="ref"}. Stroke was also ascertained from participant report of physician‐diagnosed stroke with duration of symptoms ≥ 24 h and from Hospital Episode Statistics (diagnostic ICD‐9 codes 430 to 439 or ICD‐10 codes I600 to I698).

We examined descriptive statistics for demographics, cardiometabolic risk factors, medication use and CVD outcomes by ethnicity and glycaemic status. Logistic and linear regression techniques determined age‐ and sex‐adjusted group differences. Glycaemic status by OGTT or HbA~1c~ criteria was contrasted graphically in each ethnic group, using OGTT then HbA~1c~ categories in turn as the referent groups. To enhance power and address potential ethnic presentation biases, we combined established and subclinical disease outcomes for CHD and cerebrovascular disease (subclinical disease defined as coronary artery calcification \>400 AU and brain infarct ≥3 mm, respectively). In addition, we created a composite CVD prevalence outcome (comprising CHD or cerebrovascular disease). Each outcome was examined by glycaemic status and ethnicity.

Following this, associations between glycaemic status and CHD, cerebrovascular disease or CVD were evaluated using age‐ and sex‐adjusted logistic regression models within each ethnic group. We then further adjusted these models for potential confounders (smoking, systolic blood pressure, triglycerides and waist--hip ratio), selected on the basis of significant associations with any CVD indicator and either prediabetes measure. We explored replacing waist--hip ratio with the more direct measure of visceral adipose tissue on CT in multivariate models, but this made little qualitative difference to our findings, so we present data adjusted for waist--hip ratio as the more familiar measure. To gauge the relative merit of each prediabetes measure for the prediction of CVD in each ethnic group, we compared C‐statistics for age‐ and sex‐adjusted models of CVD with models with the addition of either prediabetes measure.

Analyses were repeated using ADA HbA~1c~ criteria for prediabetes. We further adjusted multivariable models for medication use (as a sensitivity analysis because of data sparsity). Analyses were conducted in [stata]{.smallcaps} 13 (College Station, TX, USA), with *P* values \<0.05 taken to indicate statistical significance.

Results {#dme12895-sec-0008}
=======

Overt diabetes was more prevalent, and waist--hip ratio and systolic blood pressure higher, while HDL cholesterol was lower in the South Asian group than in the European group (Table [1](#dme12895-tbl-0001){ref-type="table-wrap"}). Irrespective of ethnic group, increasing glycaemia was associated with worsening of cardiometabolic risk factors (Table S1).

###### 

Characteristics of participants in the Southall and Brent Revisited study, by ethnicity

                                                                                                  European ethnicity   South Asian ethnicity   *P* [b](#dme12895-note-0003){ref-type="fn"}
  ----------------------------------------------------------------------------------------------- -------------------- ----------------------- ---------------------------------------------
  Number of participants                                                                          682                  520                     --
  Median (IQR) age, years                                                                         70 (65--75)          68 (64--73)             0.006
  Female sex, *n* (%)                                                                             153 (22)             78 (15)                 0.001
  Ever smoked                                                                                     426 (63)             113 (22)                \<0.001
  Median (IQR) alcohol consumption, units/ week                                                   5 (1--14)            4 (1--8)                \<0.001
  Median (IQR) physical activity, MJ/ week                                                        9.4 (6.8--12.1)      8.8 (5.8--11.7)         0.001
  Mean ± [sd]{.smallcaps} waist--hip ratio                                                        0.97 ± 0.07          1.00 ± 0.07             \<0.001
  Mean ± sd BMI, kg/m^2^                                                                          28 ± 5               26 ± 4                  \<0.001
  Mean ± [sd]{.smallcaps} systolic blood pressure, mmHg                                           138 ± 17             142 ± 18                \<0.001
  Mean ± sd diastolic blood pressure, mmHg                                                        77 ± 10              76 ± 10                 0.009
  Mean ± [sd]{.smallcaps} HDL cholesterol, mmol/l                                                 1.4 ± 0.4            1.3 ± 0.3               0.001
  Median (IQR) triglycerides, mmol/l                                                              1.1 (0.9--1.6)       1.2 (0.9--1.7)          0.09
  Median (IQR) C‐reactive protein, mmol/l                                                         1.7 (0.8--3.6)       1.4 (0.7--3.0)          0.01
  Anti‐hypertensive medication, *n* (%)                                                           371 (54)             395 (76)                \<0.001
  Lipid‐lowering medication, *n* (%)                                                              330 (48)             354 (68)                \<0.001
  Glycaemic status: OGTT, *n* (%)                                                                                                              
  Normoglycaemia                                                                                  377 (55)             201 (39)                \<0.001
  Prediabetes                                                                                     172 (25)             99 (19)                 0.01
  Diabetes[a](#dme12895-note-0002){ref-type="fn"}                                                 133 (20)             220 (42)                \<0.001
  Glycaemic status: HbA1c, *n* (%)                                                                                                             
  Normoglycaemia                                                                                  374 (55)             136 (26)                \<0.001
  Prediabetes                                                                                     177 (26)             146 (28)                0.37
  Diabetes[a](#dme12895-note-0002){ref-type="fn"}                                                 131 (19)             238 (46)                \<0.001
  CHD, *n* (%)                                                                                                                                 
  Clinical CHD                                                                                    142 (21)             189 (36)                \<0.001
  Coronary artery calcification \>400 AU                                                          119 (23)             72 (22)                 0.79
  Clinical CHD or coronary artery calcification[c](#dme12895-note-0004){ref-type="fn"} \>400 AU   261 (38)             258 (50)                \<0.001
  Cerebrovascular disease, *n* (%)                                                                                                             
  Stroke                                                                                          32 (5)               25 (5)                  0.68
  Brain infarct ≥3 mm                                                                             126 (21)             94 (19)                 0.92
  Stroke or brain infarct ≥3 mm                                                                   141 (23)             105 (21)                0.94
  CHD or cerebrovascular disease, *n* (%)                                                         335 (49)             296 (57)                0.001

AU, Agatston units; CHD, coronary heart disease; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; IQR, interquartile range; OGTT, oral glucose tolerance test.

Includes pre‐existing and newly diagnosed diabetes. Prediabetes by OGTT criteria comprised IFG and/or IGT.

Age and sex‐adjusted *P* value for ethnic difference, when compared with European participants.

Measured in participants without known CHD.

John Wiley & Sons, Ltd

In the South Asian but not the European participants, there was a 1.5‐fold increase in the prevalence of prediabetes when HbA~1c~ rather than OGTT criteria were used (Table [1](#dme12895-tbl-0001){ref-type="table-wrap"}). When ADA HbA~1c~ thresholds were used rather than OGTT criteria, the prevalence of prediabetes doubled for both European and South Asian participants (Table S2). South Asian participants had more clinical CHD and overall CVD (CHD + cerebrovascular disease) than European participants, although there were no differences between the ethnic groups in the prevalence of subclinical CHD or subclinical and clinical cerebrovascular disease (Table [1](#dme12895-tbl-0001){ref-type="table-wrap"}).

Differences in classification were examined by comparing glycaemic status according to either diagnostic criterion, using OGTT categories as the index classification, and excluding those with existing diabetes (Fig. [1](#dme12895-fig-0001){ref-type="fig"}a). With the exception of normoglycaemia in Europeans, agreement was poor (40--49%) for all categories in all groups, with a tendency for South Asian participants to be placed in a more adverse glycaemic category by HbA~1c~ classification. When HbA~1c~ categories were used as the reference (Fig. [1](#dme12895-fig-0001){ref-type="fig"}b), there was good agreement (71--75%) for normoglycaemia in both ethnic groups, but poor agreement for prediabetes and diabetes, especially for South Asian participants.

![(a) Glycaemia categorized by oral glucose tolerance test (OGTT) vs. HbA~1c~, by ethnicity. Diabetes comprises newly diagnosed cases only. (b) Glycaemia categorized by HbA~1c~ vs. OGTT, by ethnicity. Diabetes comprised newly diagnosed cases only.](DME-33-340-g001){#dme12895-fig-0001}

In the European group, CHD, cerebrovascular disease and CVD were more prevalent in prediabetes (by either criterion) than participants with normoglycaemia (Table [2](#dme12895-tbl-0002){ref-type="table-wrap"}). A similar, but less pronounced, pattern was seen in South Asian participants. This was even less marked when we examined disease prevalence by ADA HbA~1c~ thresholds, in both the European and South Asian groups (Table S3). When subclinical and clinical CVD measures were examined separately, similar patterns were seen (Table S4). Notably, the prevalence of clinical CHD in the South Asian participants with normoglycaemia was similar to that observed in the European participants with prediabetes.

###### 

Cardiovascular disease prevalence by ethnicity and glycaemic status in the Southall and Brent Revisited study

  Atherosclerosis measure                                         Glycaemia measure   European group, *n* (%)                                South Asian group, *n* (%)                                                                                                                                                   
  --------------------------------------------------------------- ------------------- ------------------------------------------------------ ----------------------------------------------------- ----------------------------------------------------- --------- ------------------------------------------------------ ------------------------------------------------------
  CHD: clinical or coronary artery calcification score \>400 AU   OGTT                116 (31)                                               71 (41)[\*](#dme12895-note-0006){ref-type="fn"}       74 (56)[\*\*\*](#dme12895-note-0006){ref-type="fn"}   76 (38)   47 (47)                                                135 (61)[\*\*\*](#dme12895-note-0006){ref-type="fn"}
  HbA~1c~                                                         104 (28)            78 (44)[\*\*](#dme12895-note-0006){ref-type="fn"}      79 (60)[\*\*\*](#dme12895-note-0006){ref-type="fn"}   49 (36)                                               60 (41)   149 (63)[\*\*\*](#dme12895-note-0006){ref-type="fn"}   
  Cerebrovascular disease: stroke or brain infarct ≥3 mm          OGTT                70 (21)                                                41 (26)[\*](#dme12895-note-0006){ref-type="fn"}       30 (27)                                               29 (15)   15 (16)                                                61 (31)[\*\*](#dme12895-note-0006){ref-type="fn"}
  HbA~1c~                                                         63 (18)             47 (31)[\*](#dme12895-note-0006){ref-type="fn"}        31 (27)                                               18 (14)                                               28 (20)   59 (27)[\*](#dme12895-note-0006){ref-type="fn"}        
  CHD or cerebrovascular disease                                  OGTT                155 (41)                                               94 (55)[\*\*](#dme12895-note-0006){ref-type="fn"}     86 (65)[\*\*\*](#dme12895-note-0006){ref-type="fn"}   90 (45)   51 (52)                                                155 (70)[\*\*\*](#dme12895-note-0006){ref-type="fn"}
  HbA~1c~                                                         140 (37)            106 (60)[\*\*\*](#dme12895-note-0006){ref-type="fn"}   89 (68)[\*\*\*](#dme12895-note-0006){ref-type="fn"}   60 (44)                                               71 (49)   165 (69)[\*\*\*](#dme12895-note-0006){ref-type="fn"}   

AU, Agatston units; CHD, coronary heart disease; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test.

Sex‐ and age‐adjusted *P* value for difference between prediabetes or diabetes and normoglycaemia: \*\*\*p \< 0.001, \*\*p \< 0.01, \*p \< 0.05.

Diabetes includes pre‐existing and newly diagnosed diabetes by the relevant criterion. Prediabetes by OGTT criteria comprised IFG and/or IGT.

John Wiley & Sons, Ltd

In age‐ and sex‐adjusted models of CHD or cerebrovascular disease, prediabetes by either criterion appeared to be related to disease risk in the European group **(**Table [3](#dme12895-tbl-0003){ref-type="table-wrap"}). Accounting for smoking, systolic blood pressure, triglycerides and waist--hip ratio attenuated these associations, but risks remained elevated for people with prediabetes and statistical significance was retained for HbA~1c~‐defined prediabetes. Prediabetes by either criterion was associated with overall CVD, with associations being of higher magnitude when defined by HbA~1c~ rather than OGTT. By contrast, in South Asian participants, non‐significant associations were present between OGTT‐defined prediabetes only and CHD \[odds ratio 1.39 (95% CI 0.84, 2.29)\] and HbA~1c~‐defined prediabetes only and cerebrovascular disease \[odds ratio 1.41 (95% CI 0.72, 2.76)\]). Prediabetes by either criterion appeared unrelated to CVD in this group. Associations between prediabetes by HbA~1c~ and CVD were greater in the European than in the South Asian group (ethnicity interaction *P* = 0.04, respectively). Analyses using ADA HbA~1c~ thresholds showed similar patterns to the main results (Table S5).

###### 

Multivariable models of cardiovascular disease by ethnicity and glycaemic status in the Southall and Brent Revisited study

  Glycaemia measure                                                    European group                                                South Asian group                                                                                                                                                                                                                                         
  ---------------------------------------------------------------- --- ------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------
  CHD (clinical or coronary artery calcification score \>400 AU)                                                                                                                                                                                                                                                                                                                               
  OGTT                                                             1   1                                                             1.55 (1.05,2.29)[\*](#dme12895-note-0010){ref-type="fn"}        2.86 (1.87,4.38)[\*\*\*](#dme12895-note-0010){ref-type="fn"}    1                                                         1.39 (0.84,2.29)                                                2.53 (1.69,3.79)[\*\*\*](#dme12895-note-0010){ref-type="fn"}
  2                                                                1   1.46 (0.98,2.19)                                              2.53 (1.61,3.98)[\*\*\*](#dme12895-note-0010){ref-type="fn"}    1                                                               1.41 (0.84,2.36)                                          2.26 (1.48,3.45)[\*\*\*](#dme12895-note-0010){ref-type="fn"}    
  HbA~1c~                                                          1   1                                                             1.70 (1.15,2.51)[\*\*](#dme12895-note-0010){ref-type="fn"}      3.79 (2.45,5.86)[\*\*\*](#dme12895-note-0010){ref-type="fn"}    1                                                         1.15 (0.70,1.90)                                                2.88 (1.84,4.53)[\*\*\*](#dme12895-note-0010){ref-type="fn"}
  2                                                                1   1.60 (1.07,2.39)[\*](#dme12895-note-0010){ref-type="fn"}      3.42 (2.15,5.42)[\*\*\*](#dme12895-note-0010){ref-type="fn"}    1                                                               1.06 (0.64,1.77)                                          2.50 (1.56,4.02)[\*\*\*](#dme12895-note-0010){ref-type="fn"}    
  Cerebrovascular disease (stroke or brain infarct≥3 mm)                                                                                                                                                                                                                                                                                                                                       
  OGTT                                                             1   1                                                             1.42 (0.90,2.25)                                                1.28 (0.77,2.13)                                                1                                                         0.91 (0.45,1.86)                                                2.49 (1.48, 4.18)\*\*
  2                                                                1   1.25 (0.63,1.88)                                              1.09 (0.63,1.95)                                                1                                                               1.02 (0.49,4.44)                                          2.58 (1.49, 4.44)[\*\*](#dme12895-note-0010){ref-type="fn"}     
  HbA~1c~                                                          1   1                                                             1.73 (1.10, 2.72)[\*](#dme12895-note-0010){ref-type="fn"}       1.49 (0.90, 2.49)                                               1                                                         1.41 (0.72,2.76)                                                2.18 (1.19, 4.00)[\*](#dme12895-note-0010){ref-type="fn"}
  2                                                                1   1.57 (1.00, 2.51)[\*](#dme12895-note-0010){ref-type="fn"}     1.29 (0.75,2.22)                                                1                                                               1.39 (0.69,2.78)                                          2.22 (1.17, 4.22)[\*](#dme12895-note-0010){ref-type="fn"}       
  CHD or cerebrovascular disease                                                                                                                                                                                                                                                                                                                                                               
  OGTT                                                             1   1                                                             1.72 (1.17, 2.54)[\*\*](#dme12895-note-0010){ref-type="fn"}     2.60 (1.68, 4.00)[\*\*\*](#dme12895-note-0010){ref-type="fn"}   1                                                         1.19 (0.72,1.98)                                                2.89 (1.91, 4.39)[\*\*\*](#dme12895-note-0010){ref-type="fn"}
  2                                                                1   1.58 (1.07, 2.36)[\*](#dme12895-note-0010){ref-type="fn"}     2.35 (1.47, 3.73)[\*\*\*](#dme12895-note-0010){ref-type="fn"}   1                                                               1.20 (0.71, 2.02)                                         2.64 (1.71, 4.08)[\*\*\*](#dme12895-note-0010){ref-type="fn"}   
  HbA~1c~                                                          1   1                                                             2.10 (1.43, 3.08)[\*\*\*](#dme12895-note-0010){ref-type="fn"}   3.39 (2.18, 5.28)[\*\*\*](#dme12895-note-0010){ref-type="fn"}   1                                                         1.10 (0.67,1.79)[†](#dme12895-note-0011){ref-type="fn"}         2.79 (1.77, 4.39)[\*\*\*](#dme12895-note-0010){ref-type="fn"}
  2                                                                1   1.95 (1.31, 2.91)[\*\*](#dme12895-note-0010){ref-type="fn"}   3.15 (1.96, 5.05)[\*\*\*](#dme12895-note-0010){ref-type="fn"}   1                                                               1.00 (0.61,1.66)[†](#dme12895-note-0011){ref-type="fn"}   2.63 (1.64, 4.22)[\*\*\*](#dme12895-note-0010){ref-type="fn"}   

AU, Agatston units; CHD, coronary heart disease; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test.

Data are odds ratios (95% CI) for the presence of cardiovascular disease.

\*\*\**P* \< 0.001, \*\**P* \< 0.01, \**P* \< 0.05 for difference between prediabetes or diabetes and normoglycaemia.

†*P* \< 0.05 for ethnic difference, when compared with Europeans. Diabetes includes pre‐existing and newly diagnosed diabetes by the relevant criterion. Prediabetes by OGTT criteria comprised IFG and/or IGT. Model 1: adjusted for age + sex; model 2: adjusted for age + sex + smoking status + systolic blood pressure + triglycerides (log‐transformed)) + waist--hip ratio.

John Wiley & Sons, Ltd

When either measure of prediabetes was added to age‐ and sex‐adjusted models of CVD, there were no improvements in the C‐statistic for South Asian participants; however, addition of either OGTT‐ or HbA~1c~‐defined prediabetes to models marginally improved the C‐statistic in Europeans, more so for the latter \[from 0.695 (95% CI 0.632, 0.758) to 0.705 (95% CI 0.642, 0.767)\] with addition of OGTT‐defined impaired glucose regulation (*P* = 0.20) or 0.708 (95% CI 0.646, 0.769\] with addition of HbA~1c~‐defined impaired glucose regulation (*P* = 0.008).

Finally, further adjustment of the multivariable models for receipt of antihypertensive or lipid‐lowering medication (Table S6) did not alter the main results.

Discussion {#dme12895-sec-0009}
==========

There was a marked ethnic variation in prediabetes by different diagnostic criteria [2](#dme12895-bib-0002){ref-type="ref"}, [3](#dme12895-bib-0003){ref-type="ref"}, [4](#dme12895-bib-0004){ref-type="ref"}, with a higher prevalence in South Asian but not European participants, when prediabetes was defined by HbA~1c~ rather than OGTT criteria. Furthermore, prediabetes appeared to relate differently to cardiovascular disease according to diagnostic criteria and ethnicity; HbA~1c~‐defined prediabetes was associated with CHD and cerebrovascular disease in the European group, but with only cerebrovascular disease (non‐significantly) in the South Asian group. Furthermore, there was some evidence of a weak association between OGTT‐defined prediabetes and CHD in the European and South Asian groups. Prediabetes by either criterion was associated with total CVD (CHD + cerebrovascular disease) in the European but not the South Asian group.

When HbA~1c~, as opposed to OGTT, criteria were used to define prediabetes, South Asian participants had a higher prevalence of prediabetes, reflecting previous work [5](#dme12895-bib-0005){ref-type="ref"}. This may indicate ethnic differences in the propensity to glycate haemoglobin [18](#dme12895-bib-0018){ref-type="ref"} or in pathways to overt hyperglycaemia [19](#dme12895-bib-0019){ref-type="ref"}.

Reflecting established ethnic differences in CVD, the South Asian group had greater clinical CHD than did the European group [11](#dme12895-bib-0011){ref-type="ref"}; however, proportions with subclinical CHD were similar in European and South Asian participants, which might be explained by our previous finding that coronary artery calcification scores are less related to coronary artery stenosis on angiography in South Asian than in European people [20](#dme12895-bib-0020){ref-type="ref"}. Also of note, South Asian participants in the normoglycaemic category (by any criteria) had clinical CHD rates akin to those of the European participants in the prediabetes category, implying that even normoglycaemia is a relatively high risk state in South Asian people, and thus risk factor management at the prediabetes stage may be too late.

In the European participants, associations between prediabetes by either criteria and CHD support the argument for preventative interventions at this stage of glycaemia and are consistent with previous studies reporting the effects of IFG/IGT [7](#dme12895-bib-0007){ref-type="ref"}, [21](#dme12895-bib-0021){ref-type="ref"}, [22](#dme12895-bib-0022){ref-type="ref"} and HbA~1c~ [23](#dme12895-bib-0023){ref-type="ref"}. This was less clear for the South Asian participants, for whom only IFG/IGT‐defined prediabetes appeared detrimental. We are unaware of any studies comparing associations between prediabetes and CHD risk in European and South Asian participants, although a study of South Asian and European participants living in Canada found similar associations between HbA~1c~ and carotid intima media thickness [24](#dme12895-bib-0024){ref-type="ref"}. The underlying explanations for ethnic differences in the effects of glycaemia are not clear, and probably involve a combination of genetic, epigenetic and lifestyle factors.

Associations between HbA~1c~‐defined prediabetes and cerebrovascular disease appeared similar in the two ethnic groups, although OGTT‐defined prediabetes was associated (albeit weakly) with cerebrovascular disease in the European participants only; again, explanations are not obvious. A meta‐analysis of studies examining associations between IFG or IGT and stroke suggested that IGT was modestly associated with stroke [25](#dme12895-bib-0025){ref-type="ref"}, but a study comparing associations between IFG or HbA~1c~‐defined prediabetes in white and black populations in the USA found that HbA~1c~‐defined prediabetes, but not IFG, was adversely related to stroke risk [26](#dme12895-bib-0026){ref-type="ref"}. This latter study reflects our findings to some extent, but we used more stringent HbA~1c~ thresholds (IEC, as opposed to ADA criteria), more representative of UK clinical practice [27](#dme12895-bib-0027){ref-type="ref"}. As far as we know, there are no studies comparing the effect of prediabetes on cerebrovascular disease in European and South Asian cohorts.

Importantly, OGTT‐, and in particular, HbA~1c~‐defined prediabetes appeared to be related to overall CVD risk in the European but not in the South Asian group. This suggests that prediabetes may be a less useful clinical indicator of overall CVD risk in this group, congruent with both the findings of our model discrimination analyses and concerns other authors have expressed [6](#dme12895-bib-0006){ref-type="ref"}. Explanations for this difference for HbA~1c~‐based prediabetes may lie in the greater proportions identified by this measure in these ethnic groups; that is, there is less of a differential, in terms of cardiometabolic profile, between individuals with normoglycaemia and those with prediabetes, although obviously this does not apply to OGTT‐identified individuals with prediabetes. Alternatively, the loss of differential in risk may come in the normoglycaemic group, for South Asian participants at least, in whom we showed a similar prevalence of CHD to that in European participants in the prediabetic state. Our observation that associations between prediabetes and CVD were weaker in the South Asian group than in the European group, whilst associations between diabetes itself and CVD were stronger in the South Asian group than in the European group, may suggest that South Asian people destined to transition to diabetes move faster through the prediabetes state than do European people. This speculation has support from a recent publication, suggesting that the age‐related trajectory in fasting glucose is greater in South Asian people without diabetes than in European people [28](#dme12895-bib-0028){ref-type="ref"}. Regardless, these findings, if substantiated by future studies, have crucial policy implications for prediabetes screening in ethnic minority groups.

Using the ADA rather than the IEC criteria to define prediabetes showed similar trends and ethnic differences in the association with CHD, stroke and CVD, although odds ratios were often weaker, probably reflecting the lower HbA~1c~ threshold for ADA‐defined prediabetes.

The strengths of the present study include the high prevalence of CVD outcomes. Additionally, by capturing subclinical and clinical disease, we avoided presentation bias, which may operate when comparing different ethnic groups. There were no ethnic differences in survivorship (*P* = 0.32) or follow‐up participation (*P* = 0.62) of the cohort, suggesting survivor bias is unlikely to have greatly affected the ethnic differences we found. Furthermore, numbers of events were similar in each group, therefore, differences in power by ethnicity are unlikely to explain the lack of key associations in the South Asian participants. High rates of medication usage in this elderly population may have altered associations, although adjustment for medication use did not greatly alter results and the inclusion of participants in receipt of medication is likely to render the findings more generalizable to the elderly population as a whole. Measurement error may have been a source of bias, particularly regarding glucose and HbA~1c~ measurement; there is not insubstantial biological variation in both measures [4](#dme12895-bib-0004){ref-type="ref"}. The present study only examined cross‐sectional associations; therefore, we cannot infer causality and further longitudinal research is required to replicate the findings.

In summary, the choice of diagnostic criterion for prediabetes markedly influences both the number of individuals identified in the South Asian group and the CVD risk conferred by prediabetes. When considering overall CVD risk, prediabetes was associated with risk in the European but not in the South Asian group; therefore, the use of prediabetes as a marker of CVD risk may be less clinically meaningful in this group. Of importance when considering CHD risk estimation is the observation that South Asian individuals with normoglycaemia have similar risks of CHD to European individuals with prediabetes. These novel findings have implications for CVD risk stratification and targeting of interventions in different ethnic groups, and further work is needed to substantiate them.
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